Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)

Group 1 - Acrivon Therapeutics, Inc. (ACRV) has experienced significant selling pressure, resulting in a 70.2% decline in stock price over the past four weeks, but analysts expect better earnings than previously predicted [1] - The stock is currently in oversold territory, indicated by a Relative Strength Index (RSI) reading of 25.53, suggesting a potential reversal in trend [5] - There has been a 9.7% increase in the consensus EPS estimate for ACRV over the last 30 days due to strong agreement among sell-side analysts, which typically correlates with price appreciation [7] Group 2 - ACRV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]